Abaloparatide for treating osteoporosis after menopause (TA991)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 August 2024
Romosozumab for treating severe osteoporosis (TA791)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2022
Bisphosphonates for treating osteoporosis (TA464)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 8 July 2019Published: 9 August 2017
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 7 February 2018Published: 27 October 2008
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 7 February 2018Published: 27 October 2008
Osteoporosis: assessing the risk of fragility fracture (CG146)Product type:GuidanceProgramme:Clinical guidelineLast updated: 7 February 2017Published: 8 August 2012
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 October 2010
Bindex for investigating suspected osteoporosis (MIB106)Product type:AdviceProgramme:Medtech innovation briefingPublished: 31 May 2017